The estimated Net Worth of Alan K. Smith is at least $10.3 ezer dollars as of 2 January 2020. Dr Smith owns over 3,907 units of Bellicum Pharmaceuticals Inc stock worth over $564 and over the last 8 years he sold BLCM stock worth over $9,756.
Sign up
Dr D BLCM stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Bellicum Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 3,907 units of BLCM stock worth $292 on 2 January 2020.
The largest trade he's ever made was exercising 3,907 units of Bellicum Pharmaceuticals Inc stock on 2 January 2020 worth over $292. On average, Dr trades about 372 units every 69 days since 2017. As of 2 January 2020 he still owns at least 7,545 units of Bellicum Pharmaceuticals Inc stock.
You can see the complete history of Dr Smith stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Alan K. Smith Ph.D. biography
Dr. Alan K. Smith Ph.D. is the Chief Scientific Officer at Bellicum Pharmaceuticals Inc.
How old is Dr D?
Dr D is 63, he's been the Chief Scientific Officer of Bellicum Pharmaceuticals Inc since . There are no older and 15 younger executives at Bellicum Pharmaceuticals Inc.
What's Dr D's mailing address?
Alan's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON, TX, 77030.
Insiders trading at Bellicum Pharmaceuticals Inc
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... és Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
What does Bellicum Pharmaceuticals Inc do?
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
What does Bellicum Pharmaceuticals Inc's logo look like?
Complete history of Dr Smith stock trades at Bellicum Pharmaceuticals Inc
Bellicum Pharmaceuticals Inc executives and stock owners
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Richard Fair,
President, Chief Executive Officer, Director -
Richard A. Fair,
Pres, CEO & Director -
Shane Ward,
Corporate Secretary, Chief Legal and Strategy Officer -
Charity D. Scripture M.S., Pharm.D.,
Chief Devel. Officer -
James Brown,
Independent Chairman of the Board -
Jon Stonehouse,
Independent Director -
Reid Huber,
Independent Director -
Stephen Davis,
Independent Director -
Judith Klimovsky,
Independent Director -
James Daly,
Independent Director -
David Strauss,
Corporate Controller -
Aaron Foster,
Senior Vice President, Head of Research -
Atabak Mokari,
Chief Financial Officer -
Charity Scripture,
Chief Devel. Officer -
Dr. Aaron E. Foster,
Head of Research & Sr. VP -
Dr. Alan K. Smith Ph.D.,
Chief Scientific Officer -
Joseph Senesac,
Sr. VP of Technical Operations & Quality -
Charles S. Grass,
Principal Accounting Officer -
Alan A Musso,
CFO and Treasurer -
Thomas J. Farrell,
President and CEO -
Frank B. Mc Guyer,
Director -
Alan K. Smith,
EVP, Technical Operations -
Ken Moseley,
Vice President -
Kevin M. Slawin,
CMO and CTO -
Bros. Advisors Lpbaker Feli...,
-
Peter L. Hoang,
Sr. VP of Bus. Development -
Annemarie Moseley,
Chief Operating Office and EVP -
Rosemary Y. Williams,
VP, Finance & PAO -
Gregory S. Naeve,
Chief Business Officer -
Bros. Advisors Lp Baker Bro...,
-
Edmund Harrigan,
Director -
William Grossman,
Sr. VP, Chief Medical Officer -
David M. Spencer,
Chief Scientific Officer -
Jr Joseph Paul Woodard,
SVP Clinical & Medical Affairs -
Joseph Senesac,
VP of Manufacturing -
Investments Ltd. Mc Guyer,
10% owner -
Ventures Llc Remeditex,
10% owner -
Charity Scripture,
Chief Development Officer -
Bros. Advisors Lpbaker Juli...,